Innovative Assays

We have developed a number of new assay prototypes addressing unmet clinical needs, for example:

• Vitamin D: peptide-based technology enabling direct immunoassay formats for small molecules with enhanced sensitivity and broader dynamic ranges.
• AMH: competitive assay based on new affinity reagents, alternative to traditional antibodies.

Engineering Biomaterials for Complex Targets

Our team has developed:

• Highly specific antigens for differential detection of IgMs and IgGs in infectious diseases.
• Novel biomaterials to serve as calibrators and controls in assays for infectious and coagulation markers.

Designing Smarter Biomaterials with In Silico Tools

We use in silico and AI tools to support the rational design of biomaterials and improve assay development. These predictive approaches help us:

• Anticipate protein behavior under physiological conditions
• Identify optimal regions for interaction and binding
• Refine molecular structures to enhance assay performance

By integrating these tools early in the development process, we reduce experimental cycles and accelerate the path from concept to functional immunoassay.

Accelerating Immunoassay Development

We have implemented a high-throughput platform that dramatically reduces development timelines:

• Automated workflows allow parallel analysis of multiple parameters during biomaterial and assay development projects.

This approach has improved reproducibility and de-risked early-stage development.

Synthetic Reagent Alternatives

We have validated synthetic polymers as alternatives to traditional blocking agents:

• These materials have shown comparable performance to conventional proteins (such as BSA) in different immunoassays.
• Benefits include improved stability and reduced variability in buffer formulations.